List of Contents

US mRNA Therapeutics Market Size, Share, and Trends 2024 to 2033

US mRNA Therapeutics Market (By Type: Therapeutic Vaccines, Prophylactic Vaccines, Therapeutic Drugs; By Application: Respiratory Diseases, Oncology, Rare Genetic Diseases, Infectious Diseases, Others; By End-use: Research Organizations, Hospitals & Clinics, Others) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2033

  • Last Updated : May 2024
  • Report Code : 3862
  • Category : Healthcare

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on US mRNA Therapeutics Market 

5.1. COVID-19 Landscape: US mRNA Therapeutics Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. US mRNA Therapeutics Market, By Type

8.1. US mRNA Therapeutics Market, by Type, 2024-2033

8.1.1 Therapeutic Vaccines

8.1.1.1. Market Revenue and Forecast (2021-2033)

8.1.2. Prophylactic Vaccines

8.1.2.1. Market Revenue and Forecast (2021-2033)

Chapter 9. US mRNA Therapeutics Market, By Application

9.1. US mRNA Therapeutics Market, by Application, 2024-2033

9.1.1. Oncology

9.1.1.1. Market Revenue and Forecast (2021-2033)

9.1.2. Rare Genetic Diseases

9.1.2.1. Market Revenue and Forecast (2021-2033)

9.1.3. Infectious Diseases

9.1.3.1. Market Revenue and Forecast (2021-2033)

9.1.4. Others

9.1.4.1. Market Revenue and Forecast (2021-2033)

Chapter 10. US mRNA Therapeutics Market, By End-use 

10.1. US mRNA Therapeutics Market, by End-use, 2024-2033

10.1.1. Research Organizations

10.1.1.1. Market Revenue and Forecast (2021-2033)

10.1.2. Hospitals & Clinics

10.1.2.1. Market Revenue and Forecast (2021-2033)

10.1.3. Others

10.1.3.1. Market Revenue and Forecast (2021-2033)

Chapter 11. US mRNA Therapeutics Market, Trend Forecast

11.1. US

11.1.1. Market Revenue and Forecast, by Type (2021-2033)

11.1.2. Market Revenue and Forecast, by Application (2021-2033)

11.1.3. Market Revenue and Forecast, by End-use (2021-2033)

US mRNA Therapeutics Market

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on US mRNA Therapeutics Market 

5.1. COVID-19 Landscape: US mRNA Therapeutics Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. US mRNA Therapeutics Market, By Type

8.1. US mRNA Therapeutics Market, by Type, 2024-2033

8.1.1 Therapeutic Vaccines

8.1.1.1. Market Revenue and Forecast (2021-2033)

8.1.2. Prophylactic Vaccines

8.1.2.1. Market Revenue and Forecast (2021-2033)

8.1.3. Therapeutic Drugs

8.1.3.1. Market Revenue and Forecast (2021-2033)

Chapter 9. US mRNA Therapeutics Market, By Application

9.1. US mRNA Therapeutics Market, by Application, 2024-2033

9.1.1. Respiratory Diseases

9.1.1.1. Market Revenue and Forecast (2021-2033)

9.1.2. Oncology

9.1.2.1. Market Revenue and Forecast (2021-2033)

9.1.3. Rare Genetic Diseases

9.1.3.1. Market Revenue and Forecast (2021-2033)

9.1.4. Infectious Diseases

9.1.4.1. Market Revenue and Forecast (2021-2033)

9.1.5. Others

9.1.5.1. Market Revenue and Forecast (2021-2033)

Chapter 10. US mRNA Therapeutics Market, By End-use 

10.1. US mRNA Therapeutics Market, by End-use, 2024-2033

10.1.1. Research Organizations

10.1.1.1. Market Revenue and Forecast (2021-2033)

10.1.2. Hospitals & Clinics

10.1.2.1. Market Revenue and Forecast (2021-2033)

10.1.3. Others

10.1.3.1. Market Revenue and Forecast (2021-2033)

Chapter 11. US mRNA Therapeutics Market, Trend Forecast

11.1. US

11.1.1. Market Revenue and Forecast, by Type (2021-2033)

11.1.2. Market Revenue and Forecast, by Application (2021-2033)

11.1.3. Market Revenue and Forecast, by End-use (2021-2033)

Chapter 12. Company Profiles

12.1. GSK plc.

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. BioNTech SE

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. CureVac N.V.

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. Sangamo Therapeutics, Inc.

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Translate Bio, Inc.

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. Moderna, Inc.

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Argos Therapeutics Inc.

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Arcturus Therapeutics

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. AstraZeneca plc.

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. Pfizer Inc.

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms

Proceed To Buy

USD 3800
USD 2100
USD 2100
USD 7500
Immediate Delivery Available

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client

down-arrow-imgGet a Sample

Connect with us now; your solution awaits on the other side!

Contact Us